Tonix Pharmaceuticals Holding Corp (TNXP)

Name: Tonix Pharmaceuticals Holding Corp Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-03-31

Latest Quarter

2025-03-31

Revenue

$2.4M

Net Income

$0.0

Operating Margin

-660.9%

Free Cash Flow

-$61.0M

Debt / Assets

14.3%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Tonix Pharmaceuticals Holding Corp (TNXP).
Income Statement (Quarterly)	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Revenue	2,429,000	2,582,000	2,822,000	2,208,000
Cost of Revenue	943,000	1,183,000	1,555,000	3,367,000
Gross Profit	1,486,000	1,399,000	1,267,000	-1,159,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	10,104,000	15,582,000	7,707,000	7,502,000
Operating Expenses	17,540,000	23,879,000	16,821,000	17,200,000
Operating Income	-16,054,000	-22,480,000	-15,554,000	-18,359,000
Interest Expense	0	0	0	0
Income Before Tax	0	-22,108,000	-14,213,000	-78,776,000
Income Tax Expense	0	43,000	0	0
Net Income	0	-22,108,000	-14,213,000	-78,776,000
Per Share
EPS	-2.84	-977.00	-23.00	-1,928.00
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Tonix Pharmaceuticals Holding Corp (TNXP).
Income Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Revenue	10,094,000	7,768,000	0	0	0
Cost of Revenue	7,765,000	4,741,000	112,091,000	0	0
Gross Profit	2,329,000	3,027,000	-112,091,000	0	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	40,101,000	34,752,000	30,215,000	0	14,354,000
Operating Expenses	80,073,000	121,407,000	112,091,000	92,312,000	50,511,000
Operating Income	-77,744,000	-118,380,000	-112,091,000	-92,312,000	-50,511,000
Interest Expense	0	0	-7,912,000	0	0
Income Before Tax	-130,036,000	-116,658,000	-110,218,000	0	-50,463,000
Income Tax Expense	-1,167,000	0	4,786,000	0	0
Net Income	-130,036,000	-116,658,000	-115,004,000	-92,287,000	-50,463,000
Per Share
EPS	-3,504.00	-6,368.84	-20.11	-0.98	-0.55
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Tonix Pharmaceuticals Holding Corp (TNXP).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	98,776,000	24,948,000	120,229,000	178,660,000
Short Term Investments	0	0	0	0
Net Receivables	7,904,000	4,590,000	8,043,000	7,726,000
Inventory	8,408,000	14,147,000	-8,043,000	0
Total Current Assets	119,002,000	47,768,000	130,777,000	189,049,000
Property Plant Equipment	42,817,000	94,852,000	94,529,000	51,472,000
Goodwill and Intangibles	120,000	10,708,000	120,000	0
Total Assets	162,890,000	154,457,000	225,690,000	240,900,000
Liabilities
Account Payables	4,546,000	3,782,000	8,068,000	0
Short Term Debt	3,368,000	2,620,000	432,000	489,000
Total Current Liabilities	18,307,000	18,884,000	18,180,000	21,716,000
Long Term Debt	5,025,000	7,193,000	328,000	467,000
Total Liabilities	23,332,000	48,932,000	18,508,000	22,183,000
Shareholders Equity
Retained Earnings	-730,694,000	-600,658,000	-470,038,000	-359,820,000
Total Shareholders Equity	139,558,000	105,525,000	207,182,000	218,717,000

Balance sheet annual history for Tonix Pharmaceuticals Holding Corp (TNXP).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	98,776,000	24,948,000	120,229,000	178,660,000	77,068,000
Short Term Investments	0	0	0	0	0
Net Receivables	7,904,000	4,590,000	8,043,000	7,726,000	7,627,000
Inventory	8,408,000	14,147,000	-8,043,000	0	0
Total Current Assets	119,002,000	47,768,000	130,777,000	189,049,000	87,989,000
Property Plant Equipment	42,817,000	94,852,000	94,529,000	51,472,000	9,829,000
Goodwill and Intangibles	120,000	10,708,000	120,000	0	120,000
Total Assets	162,890,000	154,457,000	225,690,000	240,900,000	98,183,000
Liabilities
Account Payables	4,546,000	3,782,000	8,068,000	0	4,598,000
Short Term Debt	3,368,000	2,620,000	432,000	489,000	595,000
Total Current Liabilities	18,307,000	18,884,000	18,180,000	21,716,000	9,819,000
Long Term Debt	5,025,000	7,193,000	328,000	467,000	0
Total Liabilities	23,332,000	48,932,000	18,508,000	22,183,000	10,535,000
Shareholders Equity
Retained Earnings	-730,694,000	-600,658,000	-470,038,000	-359,820,000	-267,533,000
Total Shareholders Equity	139,558,000	105,525,000	207,182,000	218,717,000	87,648,000

Cash flow quarterly history for Tonix Pharmaceuticals Holding Corp (TNXP).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-130,036,000	-116,658,000	-110,218,000	-92,287,000
Depreciation & Amortization	3,421,000	4,291,000	1,253,000	0
Stock Based Compensation	4,778,000	9,348,000	10,914,000	7,899,000
Change in Working Capital	5,775,000	-35,000	-2,000	5,781,000
Operating Cash Flow	-60,925,000	-102,003,000	-98,053,000	0
Investing Activities
Capital Expenditure	-120,000	-7,895,000	-48,147,000	-35,307,000
Investments	-120,000	-7,895,000	-48,147,000	-35,307,000
Investing Cash Flow	-120,000	-29,070,000	-48,147,000	0
Financing Activities
Debt Repayment	-2,350,000	-8,942,000	0	0
Common Stock Issued/Repurchased	140,195,000	36,517,000	47,213,000	212,389,000
Dividends Paid	0	0	-6,659,000	0
Financing Cash Flow	134,872,000	36,517,000	87,844,000	212,487,000
Summary
Free Cash Flow	-61,045,000	-109,898,000	-146,200,000	-110,864,000
Net Change in Cash	73,831,000	-95,281,000	-58,430,000	212,487,000

Cash flow annual history for Tonix Pharmaceuticals Holding Corp (TNXP).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	-130,036,000	-116,658,000	-110,218,000	-92,287,000	-50,463,000
Depreciation & Amortization	3,421,000	4,291,000	1,253,000	0	27,000
Stock Based Compensation	4,778,000	9,348,000	10,914,000	7,899,000	2,876,000
Change in Working Capital	5,775,000	-35,000	-2,000	5,781,000	-2,366,000
Operating Cash Flow	-60,925,000	-102,003,000	-98,053,000	0	-48,566,000
Investing Activities
Capital Expenditure	-120,000	-7,895,000	-48,147,000	-35,307,000	-8,564,000
Investments	-120,000	-7,895,000	-48,147,000	-35,307,000	-8,564,000
Investing Cash Flow	-120,000	-29,070,000	-48,147,000	0	-8,564,000
Financing Activities
Debt Repayment	-2,350,000	-8,942,000	0	0	0
Common Stock Issued/Repurchased	140,195,000	36,517,000	47,213,000	212,389,000	108,605,000
Dividends Paid	0	0	-6,659,000	0	451,000
Financing Cash Flow	134,872,000	36,517,000	87,844,000	212,487,000	123,105,000
Summary
Free Cash Flow	-61,045,000	-109,898,000	-146,200,000	-110,864,000	-57,130,000
Net Change in Cash	73,831,000	-95,281,000	-58,430,000	212,487,000	65,959,000